Evoke Pharma Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Evoke Pharma Inc Company

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.

Evoke Pharma Inc Info



Ticker SymbolEVOK

Company nameEvoke Pharma Inc

IPO dateSep 25, 2013

CEOMr. Matthew J. (Matt) D'Onofrio

Number of employees3

Security typeOrdinary Share

Fiscal year-endSep 25

Address420 Stevens Avenue

CitySOLANA BEACH

Stock exchangeNASDAQ Capital Market Consolidated

CountryUnited States of America

Postal code92075

Phone18583451494

Websitehttps://evokepharma.com/

Ticker SymbolEVOK

IPO dateSep 25, 2013

CEOMr. Matthew J. (Matt) D'Onofrio

Company Executives of Evoke Pharma Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Matthew J. (Matt) D'Onofrio

Chief Executive Officer, Co-Founder, Director

9.82K

+15.50%

Mr. Cam L. Garner

Independent Chairman of the Board, Co-Founder

2.33K

-0.04%

Dr. Malcolm R. Hill, Pharm.D.

Independent Director

133.00

-0.75%

Dr. Todd C. Brady, M.D., Ph.D.

Independent Director

27.00

-3.57%

Mr. Greg Pyszcymuka

Independent Director

--

Dr. Kenneth Jon (Ken) Widder, M.D.

Independent Director

--

Dr. Marilyn R. Carlson, M.D.

Chief Medical Officer

--

Mr. Benjamin C. (Ben) Smeal

Independent Director

--

Mr. Daniel Kontoh-Boateng

Investor Contact

--

Ms. Vickie W. Reed

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Matthew J. (Matt) D'Onofrio

Chief Executive Officer, Co-Founder, Director

9.82K

+15.50%

Mr. Cam L. Garner

Independent Chairman of the Board, Co-Founder

2.33K

-0.04%

Dr. Malcolm R. Hill, Pharm.D.

Independent Director

133.00

-0.75%

Dr. Todd C. Brady, M.D., Ph.D.

Independent Director

27.00

-3.57%

Mr. Greg Pyszcymuka

Independent Director

--

Dr. Kenneth Jon (Ken) Widder, M.D.

Independent Director

--

Revenue Breakdown

FY2025Q2

FY2025Q1

FY2024

FY2024Q1

FY2023

FY2022

FY2021

FY2020

No Data

By RegionUSD

Name

Revenue

Proportion

United States

3.75M

0.00%

By Business

By Region

No Data

Shareholding Stats

Updated: Mon, Nov 3

Shareholders

Shareholder Types

Shareholders

Proportion

Morgan Stanley Smith Barney LLC

10.51%

Nantahala Capital Management, LLC

9.51%

National Wealth Management Group, LLC

5.14%

Bleichroeder LP

4.41%

Citadel Advisors LLC

0.80%

Other

69.63%

Shareholders

Proportion

Morgan Stanley Smith Barney LLC

10.51%

Nantahala Capital Management, LLC

9.51%

National Wealth Management Group, LLC

5.14%

Bleichroeder LP

4.41%

Citadel Advisors LLC

0.80%

Other

69.63%

Shareholder Types

Shareholders

Proportion

Investment Advisor

20.62%

Hedge Fund

10.44%

Individual Investor

1.28%

Investment Advisor/Hedge Fund

0.50%

Other

67.16%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

26

491.93K

31.57%

+96.05K

2025Q2

34

272.65K

18.26%

-174.03K

2025Q1

37

273.02K

18.29%

-164.20K

2024Q4

38

286.68K

19.29%

-150.95K

2024Q3

39

276.54K

27.87%

-57.30K

2024Q2

39

330.88K

325.68%

-1.95K

2024Q1

46

331.84K

45.81%

+48.22K

2023Q4

42

12.65K

4.52%

-4.41K

2023Q3

46

12.52K

4.50%

-16.16K

2023Q2

47

11.87K

4.27%

-16.69K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Morgan Stanley Smith Barney LLC

163.72K

10.51%

+163.65K

+255709.38%

Aug 31, 2025

Nantahala Capital Management, LLC

148.15K

9.51%

--

Jun 30, 2025

Bleichroeder LP

68.75K

4.41%

--

Jun 30, 2025

Citadel Advisors LLC

12.54K

0.8%

-12.26K

-49.43%

Jun 30, 2025

D'Onofrio (Matthew J)

9.82K

0.63%

+1.32K

+15.50%

Mar 24, 2025

The Vanguard Group, Inc.

1.71K

0.11%

--

Aug 31, 2025

Geode Capital Management, L.L.C.

7.86K

0.5%

-19.00

-0.24%

Aug 31, 2025

Kowieski (Mark A.)

4.92K

0.32%

+4.92K

--

Mar 24, 2025

Gonyer (David A)

2.36K

0.15%

-1.00

-0.04%

Mar 24, 2025

Related ETFs



Updated: Sun, Nov 2

Name

Proportion

iShares Core S&P Total U.S. Stock Market ETF

0%

iShares Core S&P Total U.S. Stock Market ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

Jul 30, 2024

Merger

12→1

Jul 30, 2024

Merger

12→1

Jul 30, 2024

Merger

12→1

Jul 30, 2024

Merger

12→1

May 20, 2022

Merger

12→1

May 20, 2022

Merger

12→1

Date

Type

Ratio

Jul 30, 2024

Merger

12→1

Jul 30, 2024

Merger

12→1

Jul 30, 2024

Merger

12→1

Jul 30, 2024

Merger

12→1

May 20, 2022

Merger

12→1

May 20, 2022

Merger

12→1

May 20, 2022

Merger

12→1

May 20, 2022

Merger

12→1